Share Twitter LinkedIn Facebook Email Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel therapeutic interventions.
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read